Evidence map›Paper›PMID 26520060›Full record

ArticleBMC infectious diseases2015

Incidence of herpes zoster and associated events including stroke--a population-based cohort study.

Karin Sundström, Caroline E Weibull, Karin Söderberg-Löfdal, Tomas Bergström, Pär Sparén, Lisen Arnheim-Dahlström

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  12. Article
  13. Informing decisions in light of parameter uncertainty - an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karin SundströmDepartment of Laboratory Medicine, Karolinska Institutet, S-141 86, Stockholm, Sweden. Karin.sundstrom@ki.se.
Caroline E WeibullDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, S-141 86, Stockholm, Sweden. caroline.weibull@ki.se.
Karin Söderberg-LöfdalDivision of Clinical Pharmacology, Dept. of Laboratory Medicine, Karolinska Institutet, S-141 86, Stockholm, Sweden. karin.soderberg-lofdal@karolinska.se.
Tomas BergströmDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, S-405 30, Gothenburg, Sweden. tomas.bergstrom@microbio.gu.se.
Pär SparénDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, S-141 86, Stockholm, Sweden. par.sparen@ki.se.
Lisen Arnheim-DahlströmDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, S-141 86, Stockholm, Sweden. lisen.arnheim.dahlstrom@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore detailed understanding of herpes zoster (HZ) is called for in the context of an increasing observed frequency of disease, and ongoing discussions regarding potential consequences of the disease. Thus, population-based data on incidence and complications of HZ are needed.

methodsWe conducted a register-based cohort study in Västra Götaland County (population 1.5 million) in Sweden. We collected data on all patients diagnosed with HZ during the years 2008 to 2010 from population-based registers. Incidence rates (IR) of HZ and related complications were calculated and stratified by age and sex.

resultsThere were 13 269 new HZ cases during the study period. Overall, the IR of herpes zoster in both genders was 3.25 (95% CI: 3.16-3.34) per 1000 person years in 2010. The incidence was consistently higher in women than in men and in older than in young. A history of immunosuppression was more common than in the general population. The incidence was highest in individuals over 80 years of age (IR 9.2 per 1000 person years, 95% CI: 8.8-9.6) during 2008-2010. The most common complications to HZ were ocular engagement and postherpetic neuralgia; risks for stroke and sepsis were significantly elevated during the one year following diagnosis, especially in the youngest age group of patients 0-39 years.

conclusionsHerpes zoster is more common in women, the elderly and immunosuppressed individuals. We verify a population-based association between herpes zoster and risk for stroke and sepsis, which may merit concern.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCohort StudiesFemaleHerpesvirus 3, HumanHerpes ZosterHumansImmunosuppressive AgentsInfantInfant, NewbornMaleMiddle AgedImmunosuppressive Agents

Identifiers

PMID26520060
PMCPMC4628253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.